Page 11 - Compass Pathways News Today

The legalisation of psychedelic drugs could be a potential game-changer for the treatment of mental health.

{"desktop":[{"injectionEnabled":false,"componentType":"gpt","targeting":{"index":-1,"hivis":"n"},"referenceNode":"header","hideOnSensitiveArticle":true,"hideOnFirstPageView":true,"relativePos":"after","name":"div-gpt-ad-oop-slot","isOOP":true,"type":"outOfPage"},{"componentType":"gpt",&quo...

COMPASS Pathways plc (NASDAQ:CMPS) Q3 2023 Earnings Call Transcript November 4, 2023 Operator: Good day, ladies and gentlemen, and welcome to the COMPASS Pathways Third Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded. I would now like to introduce your host […]

CMPS earnings call for the period ending September 30, 2023.

Company's cash position stands at $248.0 million with a net loss of $33.4 million for Q3 2023

The active ingredient that makes magic mushrooms so magic—the psychedelic drug psilocybin—is one step closer to becoming a legal treatment for difficult

Investorideas.com a global investor news source covering psilocybin and psychedelic health and wellness stocks releases a special news report featuring Kaya Holdings, Inc. . As psilocybin and other...

Pioneers and Innovators in Psilocybin Treatments (OTCQB: KAYS) (NASDAQ: CMPS) (NYSE: CYBN) (OTC: MSSTF)

With MDMA on track to gain United States Food and Drug Administration (FDA) approval for the treatment of post-traumatic stress disorder (PTSD) in 2024, Big...

Researchers mined an old drug forum and fed the entries to an AI. The result could augur a new class of psychedelic-based antidepressants.